SCYNEXIS GAAP EPS of -$0.11 beats by $0.08, revenue of $0.26M beats by $0.12M

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SCYNEXIS Inc.

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.